Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base

Pancreatic adenocarcinoma (PAC) has low overall survival (OS) rates and high recurrence rates following surgical resection. The role for preoperative radiation therapy (prRT) for PAC versus postoperative RT (poRT) remains uncertain. The authors used the National Cancer Data Base (NCDB) to report prRT outcomes for the largest multi‐institutional patient cohort to date.

[1]  A. Krasinskas,et al.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer , 2013, Journal of surgical oncology.

[2]  Ravi Shridhar,et al.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. , 2013, International journal of radiation oncology, biology, physics.

[3]  M. Saif.  Advancements in the management of pancreatic cancer: 2013. , 2013, JOP : Journal of the pancreas.

[4]  S. Edge,et al.  Completeness of American Cancer Registry Treatment Data: implications for quality of care research. , 2013, Journal of the American College of Surgeons.

[5]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[6]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Eguchi,et al.  Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer , 2012, Annals of surgery.

[8]  Laura H. Tang,et al.  Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease , 2011, Annals of Surgical Oncology.

[9]  M. Ychou,et al.  Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[11]  P. Catalano,et al.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma , 2010, Journal of surgical oncology.

[12]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Stessin,et al.  Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. , 2008, International journal of radiation oncology, biology, physics.

[14]  C. Ko,et al.  Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. , 2008, Journal of the American College of Surgeons.

[15]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[16]  Douglas B. Evans,et al.  Tumor‐Node‐Metastasis Staging of Pancreatic Adenocarcinoma , 2008, CA: a cancer journal for clinicians.

[17]  P. Philip,et al.  A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma , 2006, Annals of Surgical Oncology.

[18]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[19]  D. Tyler,et al.  Neoadjuvant therapy for pancreatic cancer: the Duke experience. , 2004, Surgical oncology clinics of North America.

[20]  J. Blache,et al.  A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience , 2004, Journal of Gastrointestinal Surgery.

[21]  D. Kerr,et al.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial , 2001, The Lancet.

[22]  B. Eisenberg,et al.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas , 2001, Journal of Gastrointestinal Surgery.

[23]  Jeffrey E. Lee,et al.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Abbruzzese,et al.  Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. , 1995, American journal of surgery.

[25]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[26]  Jeffrey E. Lee,et al.  Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[27]  F. Viret,et al.  Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[28]  M. Saif,et al.  Advancements in the management of pancreatic cancer. , 2009, JOP : Journal of the pancreas.

[29]  Jeffrey E. Lee,et al.  Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration , 2022 .

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.